Suppr超能文献

缺血性肾病:蛋白尿和肾脏阻力指数可提示是否推荐血管再通治疗。

Ischemic nephropathy: proteinuria and renal resistance index could suggest if revascularization is recommended.

机构信息

Department of Nephrology, Sapienza University of Rome, Rome, Italy.

出版信息

Ren Fail. 2010;32(10):1167-71. doi: 10.3109/0886022X.2010.516856.

Abstract

BACKGROUND

The aim of endovascular therapy in renal artery stenosis (RAS) is to preserve renal function and have a better hypertension control. The purpose of our study was to determine which biochemical and instrumental parameters could predict a better renal outcome in patients with RAS treated with percutaneous transluminal angioplasty and stenting (RPTAS).

METHODS

We performed an observational study based on 40 patients with RAS who met the following criteria before revascularization: urinary protein excretion of over 250 mg/24 h, normal renal function, and/or mild-moderate renal insufficiency (I, II, and III levels of classification of chronic kidney disease, K-DOQI).

RESULTS

Assessment at 12 months after RPTAS showed in 20 patients (Group A) that proteinuria serum creatinine (Scr) and creatinine clearance (CrCl) significantly worsened from the baseline; whereas in 20 patients (Group B) proteinuria remained unchanged and the renal function improved after the procedure.

CONCLUSIONS

In our study, the decline of renal function after RPTAS is associated with an elevated renal resistance index (RI) in both kidneys (0.83 ± 0.2) and preexisting proteinuria.

摘要

背景

肾动脉狭窄(RAS)的血管内治疗的目的是保留肾功能并更好地控制高血压。我们研究的目的是确定哪些生化和仪器参数可以预测 RAS 患者接受经皮腔内血管成形术和支架置入术(RPTAS)治疗后的更好的肾脏结局。

方法

我们进行了一项观察性研究,共纳入了 40 名符合以下标准的 RAS 患者:在血管重建前存在蛋白尿(>250 mg/24 h)、肾功能正常和/或轻度至中度肾功能不全(慢性肾脏病 K-DOQI 分类的 I、II 和 III 级)。

结果

在 RPTAS 治疗后 12 个月,20 名患者(A 组)的血清蛋白肌酐(Scr)和肌酐清除率(CrCl)较基线显著恶化;而在 20 名患者(B 组)中,蛋白尿量保持不变,肾功能在手术后得到改善。

结论

在我们的研究中,RPTAS 后肾功能下降与双侧肾脏的肾阻力指数(RI)升高(0.83 ± 0.2)和预先存在的蛋白尿有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验